Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PolyA RNA-seq from liposarcoma cells treated with Nutlin3R

ABSTRACT: Analysis of steady-state mRNA levels in liposarcoma cells treated for 16 hr with 0.05% DMSO or 10 uM Nutlin3R

ORGANISM(S): Homo sapiens

PROVIDER: GSE214889 | GEO | 2023/05/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

PolyA RNA-seq from liposarcoma cells treated with Nutlin3R and/or Carfilzomib

Project description:Analysis of steady-state mRNA levels in liposarcoma cells treated for 28 hr with 0.05% DMSO or 10 uM Nutlin3R and/or 12.5 nM Carfilzomib

2023-05-12 | GSE226530 | GEO

PolyA RNA-seq from liposarcoma cells treated with Nutlin3R

Project description:PolyA RNA-seq from liposarcoma cells treated with Nutlin3R

| PRJNA887473 | ENA

PolyA RNA-seq from CHP212 WT and FAM193AKO cells treated with Nutlin-3

Project description:Analysis of steady-state mRNA levels in CHP212 WT and FAM193AKO cells following DMSO or Nutlin-3a treatment.

2022-12-19 | GSE189133 | GEO

Poorly differentiated, human liposarcoma LiSa-2 cell line response to the synthetic triterpenoid CDDO

Project description:Analysis of poorly differentiated LiSa-2 liposarcoma (LS) cells treated with the synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) or DMSO or a combination of CDDO and DMSO for up to 11 days. Synthetic triterpenoids exert a variety of actions, including anti-proliferative and proapoptotic effects, making them potentially useful in cancer therapy. Results provide insight into the pathogenesis of LS. Keywords: disease state analysis, CDDO effect, time course Temporal analysis of human liposarcoma cell line LiSa-2 subjected to treatment with a synthetic triterpenoid.

2010-06-25 | E-GEOD-3643 | biostudies-arrayexpress

Poorly differentiated, human liposarcoma LiSa-2 cell line response to the synthetic triterpenoid CDDO

2009-05-14 | GSE3643 | GEO

Differentiating liposarcoma from lipoma using a simple blood test: A miRNA signature

Project description:Background: Liposarcoma constitute about 13% of all soft tissue sarcoma and are associated with a high risk of metastases. As the preoperative differentiation between benign and malign lipomatous tumors is restricted to magnetic resonance imaging, computed tomography and biopsy, we performed a miRNA array to distinguish liposarcoma patients from healthy controls and lipoma patients. Workflow: Blood samples of patients with dedifferentiated liposarcoma, healthy controls and lipoma patients were collected. Whole blood RNA was extracted and samples of patients with dedifferentiated liposarcoma (n=6) and of healthy donors (n=4) were analyzed using an Affymetrix GeneChip miRNA Array v. 4.0. qRT-PCR was carried out to confirm the most differentially expressed miRNA; being further analyzed in an independent cohort of healthy controls as well as in lipoma patients. Results: As shown by the microarray, two miRNAs (miR-4668-5p and miR-3613-3p) were shown to be significantly upregulated (fold change: >2.5; p<0.05) in patients with dedifferentiated liposarcoma (n=6) as compared to healthy controls (n=4). miR-4668-5p was further validated by qRT-PCR to be significantly upregulated in liposarcoma patients compared to an independent cohort of healthy controls (n=3) and lipoma patients (n=6). Conclusion: We identified a specific whole blood miRNA (miR-4668-5p) that may serve to distinguish between lipoma and liosarcoma patients, thus potentially serving as a specific biomarker for dedifferentiated liposarcoma.

2018-06-01 | E-MTAB-5126 | biostudies-arrayexpress

PolyA RNA-seq from liposarcoma cells treated with Nutlin3R and/or Carfilzomib

Project description:PolyA RNA-seq from liposarcoma cells treated with Nutlin3R and/or Carfilzomib

| PRJNA940486 | ENA

PolyA RNA-seq from iPSCs and differentiated iPSCs treated with Nutlin-3

Project description:Analysis of steady-state mRNA levels in induced pluripotent stem cells (iPSCs), iPSCs differentiated for 5 days with retinoic acid (RA) (5d-RAI), and iPSCs differentiated to cardiomyocytes (CM), and treated with DMSO (vehicle) or the p53 inhibitor Nutlin-3.

2022-11-08 | GSE207376 | GEO

Whole genome microarray analysis in myxoid liposarcoma

Project description:In order to identify new key molecules in the pathogenesis of myxoid liposarcoma, we performed comparative gene expression profiling in myxoid liposarcoma and fat tissue samples.

2014-10-28 | GSE62747 | GEO

Whole-transcript expression data for liposarcoma

Project description:Liposarcoma is the most common soft tissue sarcoma, accounting for about 20% of cases. Liposarcoma is classified into 5 histologic subtypes that fall into 3 biological groups characterized by specific genetic alterations. To identify genes that contribute to liposarcomagenesis and to better predict outcome for patients with the disease, we undertook expression profiling of liposarcoma. U133A expression profiling was performed on 140 primary liposarcoma samples, which were randomly split into training set (n=95) and test set (n=45). A multi-gene predictor for distant recurrence-free survival (DRFS) was developed using the supervised principal component method. Expression levels of the 588 genes in the predictor were used to calculate a risk score for each patient. In validation of the predictor in the test set, patients with low risk score had a 3-year DRFS of 83% vs. 45% for high risk score patients (P=0.001). The hazard ratio for high vs. low score, adjusted for histologic subtype, was 4.42 (95% confidence interval 1.26-15.55; P=0.021). The concordance probability for risk score was 0.732. Genes related to adipogenesis, DNA replication, mitosis, and spindle assembly checkpoint control were all highly represented in the multi-gene predictor. Three genes from the predictor, TOP2A, PTK7, and CHEK1, were found to be overexpressed in liposarcoma samples of all five subtypes and in liposarcoma cell lines. Knockdown of these genes in liposarcoma cell lines reduced proliferation and invasiveness and increased apoptosis. Thus, genes identified from this predictor appear to have roles in liposarcomagenesis and have promise as therapeutic targets. In addition, the multi-gene predictor will improve risk stratification for individual patients with liposarcoma.

2011-09-02 | GSE30929 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data